Caplacizumab-Yhdp and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Caplacizumab-Yhdp
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines both make it harder for your blood to clot. Apixaban (Eliquis) is a blood thinner that prevents clots. Caplacizumab also affects clotting and, even on its own, can cause serious bleeding. Taking them together adds their effects and raises your risk of bleeding.
Signs to watch for include unusual bruising, nosebleeds, bleeding gums, pink or red urine, black stools, or bleeding that will not stop. The good news is that your care team knows how to handle this. They may avoid using both together, watch you very closely, or adjust your plan. Please do not stop or change either medicine on your own. Talk with your pharmacist or doctor about any bleeding.
Effect: Additive impairment of hemostasis, increasing bleeding risk. Neither agent is a prodrug; this is a pharmacodynamic (not PK) interaction.
- Direction: Both drugs reduce clotting; combined effect is additive bleeding risk.
- Severity/Evidence: Major severity, theoretical substantiation. Caplacizumab-yhdp alone carries a risk of life-threatening/fatal bleeding.
- Management: Avoid concomitant use if possible. If required, monitor closely for bleeding. Interrupt caplacizumab-yhdp with clinically significant bleeding. Withhold caplacizumab-yhdp 7 days before elective surgery/dental/invasive procedures; for emergencies, consider von Willebrand factor concentrate. Monitor closely when resuming.
What happens
An increased risk of bleeding
Interaction Deep Dive
Do not combine caplacizumab-yhdp with anticoagulants, because taking it alongside agents that influence hemostasis and coagulation raises bleeding risk; even caplacizumab-yhdp used on its own has been linked to bleeding that is life-threatening and fatal. When such combined use cannot be avoided, evaluate and watch the patient carefully for bleeding, particularly when caplacizumab-yhdp is reintroduced after a bleeding event. Should clinically significant bleeding develop, pause caplacizumab-yhdp. For elective surgery, dental work, or other invasive procedures, hold caplacizumab-yhdp for 7 days beforehand. When emergency surgery becomes necessary, von Willebrand factor concentrate may be considered as a way to restore hemostasis. Once the danger of surgical bleeding has passed and caplacizumab-yhdp is restarted, keep a close watch for indications of bleeding1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
The main goal is to lower bleeding risk. Because both drugs affect clotting, the general recommendation is to avoid using them together when possible.
- If your team decides you need both, they will monitor you closely for bleeding.
- Caplacizumab may be paused if significant bleeding occurs and is typically held for 7 days before planned surgery or dental work.
- Keep taking both exactly as prescribed unless your care team tells you otherwise.
- Report any bruising, nosebleeds, blood in urine or stool, or bleeding that will not stop to your pharmacist or doctor right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Caplacizumab-Yhdp and Apixaban together?
Apixaban and caplacizumab-yhdp together add up to a higher bleeding risk, so this combination is generally avoided; if both are needed, your care team will monitor you very closely for any bleeding. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Caplacizumab-Yhdp and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Caplacizumab-Yhdp and Apixaban interaction managed?
The main goal is to lower bleeding risk. Because both drugs affect clotting, the general recommendation is to avoid using them together when possible. If your team decides you need both, they will monitor you closely for bleeding. Caplacizumab may be paused if significant bleeding occurs and is typically held for 7 days before planned surgery or dental work. Keep taking both exactly as prescribed… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Caplacizumab-Yhdp or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CABLIVI® intravenous, subcutaneous injection, caplacizumab-yhdp intravenous, subcutaneous injection. Genzyme Corporation (per FDA), Cambridge, MA, 2025. DailyMed
Keep reading about Apixaban
Keep reading about Caplacizumab-Yhdp
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist